The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern
COVID-19 vaccines are playing a vital role in controlling the COVID-19 pandemic. As SARS-CoV-2 variants encoding mutations in the surface glycoprotein, Spike, continue to emerge, there is increased need to identify immunogens and vaccination regimens that provide the broadest and most durable immune responses. We compared the magnitude and breadth of the neutralizing antibody response, as well as levels of Spike-reactive memory B cells, in individuals receiving a second dose of BNT162b2 at a short (3-4 week) or extended interval (8-12 weeks) and following a third vaccination approximately 6-8 months later. We show that whilst an extended interval between the first two vaccinations can greatly increase the breadth of the immune response and generate a higher proportion of Spike reactive memory B cells, a third vaccination leads to similar levels between the two groups. Furthermore, we show that the third vaccine dose enhances neutralization activity against omicron lineage members BA.1, BA.2 and BA.4/BA.5 and this is further increased following breakthrough infection during the UK omicron wave. These findings are relevant for vaccination strategies in populations where COVID-19 vaccine coverage remains low.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
PLoS pathogens - 18(2022), 10 vom: 01. Okt., Seite e1010882 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Graham, Carl [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 17.10.2022 Date Revised 24.10.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1371/journal.ppat.1010882 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347065147 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347065147 | ||
| 003 | DE-627 | ||
| 005 | 20231226032932.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.ppat.1010882 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM347065147 | ||
| 035 | |a (NLM)36191037 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Graham, Carl |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.10.2022 | ||
| 500 | |a Date Revised 24.10.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a COVID-19 vaccines are playing a vital role in controlling the COVID-19 pandemic. As SARS-CoV-2 variants encoding mutations in the surface glycoprotein, Spike, continue to emerge, there is increased need to identify immunogens and vaccination regimens that provide the broadest and most durable immune responses. We compared the magnitude and breadth of the neutralizing antibody response, as well as levels of Spike-reactive memory B cells, in individuals receiving a second dose of BNT162b2 at a short (3-4 week) or extended interval (8-12 weeks) and following a third vaccination approximately 6-8 months later. We show that whilst an extended interval between the first two vaccinations can greatly increase the breadth of the immune response and generate a higher proportion of Spike reactive memory B cells, a third vaccination leads to similar levels between the two groups. Furthermore, we show that the third vaccine dose enhances neutralization activity against omicron lineage members BA.1, BA.2 and BA.4/BA.5 and this is further increased following breakthrough infection during the UK omicron wave. These findings are relevant for vaccination strategies in populations where COVID-19 vaccine coverage remains low | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Membrane Glycoproteins |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Lechmere, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Rehman, Aisha |e verfasserin |4 aut | |
| 700 | 1 | |a Seow, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Kurshan, Ashwini |e verfasserin |4 aut | |
| 700 | 1 | |a Huettner, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Maguire, Thomas J A |e verfasserin |4 aut | |
| 700 | 1 | |a Tam, Jerry C H |e verfasserin |4 aut | |
| 700 | 1 | |a Cox, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Ward, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Racz, Mariusz |e verfasserin |4 aut | |
| 700 | 1 | |a Waters, Anele |e verfasserin |4 aut | |
| 700 | 1 | |a Mant, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Malim, Michael H |e verfasserin |4 aut | |
| 700 | 1 | |a Fox, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Doores, Katie J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PLoS pathogens |d 2005 |g 18(2022), 10 vom: 01. Okt., Seite e1010882 |w (DE-627)NLM158124782 |x 1553-7374 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:10 |g day:01 |g month:10 |g pages:e1010882 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.ppat.1010882 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 10 |b 01 |c 10 |h e1010882 | ||